InvestorsHub Logo
Followers 3
Posts 91
Boards Moderated 0
Alias Born 07/24/2014

Re: None

Friday, 12/15/2017 9:15:03 AM

Friday, December 15, 2017 9:15:03 AM

Post# of 12450
IntelGenx Receives Health Canada Clearance to Begin Phase 2a Study with Montelukast Versafilm(TM) in Mild to Moderate Alzheimer's Disease.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News